Table 1 Demographic and clinical characteristics of the four severity groups based on CIDI.
From: Specificity of psychopathology across levels of severity: a transdiagnostic network analysis
| Ā | CIDI subthreshold (nā=ā492) | CIDI lifetime only (nā=ā205) | CIDI 12mo-no- treatment (nā=ā291) | CIDI 12mo-yes- treatment (nā=ā303) | df | Test statistics | p-value |
|---|---|---|---|---|---|---|---|
Female (%) | 47.9a | 53.9a,b | 60.1b | 60.2b | 3 | Ļā=ā14.7 | 0.002 |
Age (Mā±āSD) | 18.52a (0.61) | 18.51a (0.62) | 18.57a (0.60) | 18.58a (0.65) | 3 | Fā=ā1.0 | 0.384 |
Social Economic Status (SES) (%) | |||||||
Lowest 25% SES | 16.5a | 24.9a,b | 28.4b | 29.1b | 6 | Ļā=ā23.3 | Pā<ā0.001 |
Middle 50% SES | 53.0a | 49.2a | 49.8a | 51.9a | Ā | Ā | Ā |
Highest 25% SES | 30.5a | 25.9a,b | 21.8a,b | 19.0b | Ā | Ā | Ā |
Diagnostic categories (% 1 ) | |||||||
Anxiety disorders | 68.5# | 53.7 | 57.0 | 58.4 | Ā | Ā | Ā |
Attention Deficit Hyperactivity Disorder | 0.8# | 4.4 | 6.9 | 15.8 | Ā | Ā | Ā |
Disruptive disorders | 28.5# | 28.8 | 15.8 | 13.5 | Ā | Ā | Ā |
Mood disorders | 25.4# | 31.2 | 22.3 | 40.9 | Ā | Ā | Ā |
Substance use disorders | 18.3# | 4.9 | 16.2 | 15.2 | Ā | Ā | Ā |
Comorbidityā>ā1 subthreshold or threshold diagnosis (%) | 44.1 | 27.8 | 35.0 | 46.5 | Ā | Ā | Ā |
Adult Self Report total score (Mā±āSD) | 25.02 (16.97) | 34.90 (22.13) | 42.6 (24.60) | 51.9 (27.33) | 3 | Fā=ā99.2 | Pā<ā0.001 |
Clinical range (%) | 4.5a | 13.2b | 20.3b | 30.0c | 6 | Ļā=ā155.6 | Pā<ā0.001 |
Borderline range (%) | 6.5a | 12.7b | 12.4b | 20.1b | Ā | Ā | Ā |
Healthy range (%) | 89.0a | 74.1b | 67.4b | 49.8c | Ā | Ā | Ā |
Symptom domains (Mā±āSD): | |||||||
Core depression | 0.59a (1.02) | 0.89 b (1.13) | 1.16b (1.34) | 1.61c (1.53) | 3 | Fā=ā44.0 | Pā<ā0.001 |
Negative cognitions about oneself | 0.87a (1.22) | 1.44b (1.57) | 1.71b (1.78) | 2.34c (2.05) | 3 | Fā=ā53.1 | Pā<ā0.001 |
Fatigue | 0.74a (1.04) | 1.00a (1.07) | 1.32b (1.23) | 1.68c (1.32) | 3 | Fā=ā44.0 | Pā<ā0.001 |
Fearfulness | 0.54a (0.77) | 0.78b (0.94) | 0.92b (0.94) | 1.22c (1.16) | 3 | Fā=ā34.4 | Pā<ā0.001 |
Medically unexplained pain | 0.27a (0.79) | 0.39a (1.07) | 0.74b (1.43) | 1.10c (1.47) | 3 | Fā=ā34.5 | Pā<ā0.001 |
Worrying | 2.04a (1.70) | 2.69b (1.84) | 3.00b (1.91) | 3.73c (2.01) | 3 | Fā=ā54.4 | Pā<ā0.001 |
Impulsivity | 1.07a(1.19) | 1.49b(1.35) | 1.69b,c(1.48) | 1.96c(1.51) | 3 | Fā=ā30.1 | Pā<ā0.001 |
Attention problems | 3.40a (2.18) | 3.88 a (2.21) | 4.77 b(2.54) | 5.40 c(2.59) | 3 | Fā=ā50.7 | Pā<ā0.001 |
Hyperactivity/restlessness | 1.15a (1.12) | 1.60b (1.40) | 1.90b,c (1.39) | 2.17c (1.55) | 3 | Fā=ā41.8 | Pā<ā0.001 |
Emotion dysregulation | 0.83a (1.06) | 1.19b (1.29) | 1.39b (1.34) | 1.67c (1.37) | 3 | Fā=ā31.2 | Pā<ā0.001 |
Substance use | 0.55a (0.82) | 0.65a,b (0.88) | 0.83b (1.03) | 0.76b (1.0) | 3 | Fā=ā6.5 | Pā=ā0.001 |
Number of symptom domains endorsed (%) | |||||||
0 | 41.7a | 50.6a | 45.0a | 46.4a | 6 | Ļā=ā13.3 | Pā=ā0.04 |
1 | 26.6a | 17.1b | 24.4a,b | 18.2b | Ā | Ā | Ā |
2 or more | 31.7a | 32.2a | 30.6a | 35.4a | Ā | Ā | Ā |